2024
S733 Efficacy, Safety and Time to Response of Linaclotide in Adult Patients With Chronic Idiopathic Constipation: A Post Hoc Subgroup Analysis by Age
Chang L, Brenner D, Chen W, Yerneni N, Wu J, Feuerstadt P, Staller K. S733 Efficacy, Safety and Time to Response of Linaclotide in Adult Patients With Chronic Idiopathic Constipation: A Post Hoc Subgroup Analysis by Age. The American Journal Of Gastroenterology 2024, 119: s503-s504. DOI: 10.14309/01.ajg.0001032300.07115.42.Peer-Reviewed Original ResearchPost hoc subgroup analysisChronic idiopathic constipationIdiopathic constipationAdult patientsSubgroup analysisOutcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
Li S, Wangqin R, Pan Y, Jin A, Li H, Schwamm L, Fisher M, Campbell B, Parsons M, Wang Z, Dai H, Li D, Li R, Wang J, Wang D, Wang Y, Zhao X, Li Z, Zheng H, Xiong Y, Meng X, Wang Y. Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial. Stroke And Vascular Neurology 2024, 9: svn-2023-002694. PMID: 38296586, PMCID: PMC11791627, DOI: 10.1136/svn-2023-002694.Peer-Reviewed Original ResearchOnset to treatment timeAcute ischaemic strokeEfficacy outcomesSubgroup analysisPost hoc subgroup analysisModified Rankin Scale scoreIschaemic strokeExcellent functional outcomeAcute ischaemic stroke patientsBenefit of intravenous alteplasePooled risk differenceRankin Scale scoreSymptomatic intracranial haemorrhageControlled clinical trialsStroke onset to treatment timePost Hoc AnalysisNon-inferiority trialOpen-labelTenecteplase groupIntravenous tenecteplaseNon-inferior to alteplaseProportion of participantsReperfusion therapyIntracranial haemorrhageIntravenous alteplase
2023
Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial
Cullen N, Novak P, Tosun D, Kovacech B, Hanes J, Kontsekova E, Fresser M, Ropele S, Feldman H, Schmidt R, Winblad B, Zilka N. Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. EBioMedicine 2023, 99: 104923. PMID: 38101301, PMCID: PMC10733085, DOI: 10.1016/j.ebiom.2023.104923.Peer-Reviewed Original ResearchConceptsTau pathologyPathological tau proteinsAlzheimer's diseaseDouble-blindPlacebo-ControlledCDR-SBTau immunotherapyTau proteinPhase 2 clinical trialAnti-tauPost hoc subgroup analysisAD-related declineDisease patientsSlowing of declineAlzheimer's disease patientsAntibody-dependent mannerAADvac1Post Hoc AnalysisActive immunotherapyTauFull analysisParallel-groupSubgroup analysisBaseline MRIEfficacy assessment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply